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Abstract 
Central nervous system (CNS) relapse carries a poor prognosis in diffuse large  
B-cell lymphoma (DLBCL). Integrating biomarkers into the CNS International 
Prognostic Index (CNS-IPI) risk model may improve identification of patients at high 
risk of developing secondary CNS disease. CNS relapse was analyzed in 1,418 
DLBCL patients treated with obinutuzumab or rituximab plus CHOP 
(cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy in the phase 
III GOYA study (NCT01287741). Cell-of-origin (COO) was assessed using gene 
expression profiling. BCL2 and MYC protein expression were analyzed by 
immunohistochemistry. The impact of CNS-IPI, COO, and BCL2/MYC dual-
expression status on CNS relapse was assessed using a multivariate Cox regression 
model (data available in n = 1,418, n = 933, and n = 688, respectively). High CNS-IPI 
score (hazard ratio [HR], 4.0; 95% confidence interval [CI], 1.3‒12.3; P = .02) and 
activated B-cell‒like (ABC) (HR, 5.2; 95% CI, 2.1‒12.9; P = .0004) or unclassified 
COO subtypes (HR, 4.2; 95% CI, 1.5‒11.7; P = .006) were independently associated 
with CNS relapse. BCL2/MYC dual-expression status did not impact CNS relapse 
risk. Three risk subgroups were identified according to the presence of high CNS-IPI 
score and/or ABC/unclassified COO (CNS-IPI-C model): low risk (no risk factors, n = 
450 [48.2%]); intermediate risk (one factor, n = 408 [43.7%]); and high risk (both 
factors, n = 75 [8.0%]). Two-year CNS relapse rates were 0.5%, 4.4%, and 15.2% in 
respective risk subgroups. Combining high CNS-IPI and ABC/unclassified COO 
improved CNS relapse prediction and identified a patient subgroup at high risk of 
developing CNS relapse. 
 
Word count: 250/250 
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Introduction 
Central nervous system (CNS) relapse is a rare, usually fatal, event in diffuse large 
B-cell lymphoma (DLBCL); median overall survival (OS) after its occurrence is 3.5 to 
7 months.1,2 Addition of rituximab (R) to cyclophosphamide, doxorubicin, vincristine, 
and prednisone (CHOP) significantly improves outcomes in DLBCL patients;3,4 
however, its impact on the incidence of secondary CNS disease remains unclear, 
with some studies demonstrating reduced CNS relapse risk in DLBCL patients 
treated with R-CHOP vs CHOP5,6 and others showing similar CNS relapse rates.7 
Reliable identification of patients at higher risk of developing secondary CNS disease 
is needed. Several clinical prognostic models have been proposed.1,2,8 The CNS 
International Prognostic Index (CNS-IPI) model is the most recently developed,1 and 
was built using a large dataset of patients with aggressive B-cell lymphomas (80% 
DLBCL), who were enrolled in studies from the German High-Grade Non-Hodgkin 
Lymphoma Study Group (DSHNHL) and MabThera International Trial (MInT), and 
was successfully validated in population-based DLBCL cohorts.9,10 The model 
includes the IPI risk factors plus involvement of the kidneys and/or adrenal glands. 
Implementation of biomarkers into the CNS-IPI model may improve identification of 
patients with high risk of CNS relapse.9  
DLBCL represents a biologically heterogeneous disease with germinal center B-cell–
like (GCB) and activated B-cell–like (ABC) subtypes, each arising from different non-
malignant lymphoid counterparts.11 DLBCL cell-of-origin (COO) subtypes harbor 
specific genetic abnormalities;12-14 for example, GCB DLBCL is characterized by 
frequent translocations of the BCL2 gene and loss of PTEN, while ABC DLBCL is 
characterized by biallelic loss of the CDKN2A gene, which encodes proteins 
implicated in regulation of the cell cycle (p16INK4A) and p53 (ARF), and chronically 
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active B-cell receptor and NFκB signaling.12,15-18 The impact of COO subtype on 
prognosis has been confirmed in several studies, with the ABC subtype predicting 
worse outcomes.19,20 ABC DLBCL was also shown to be the most common COO 
subtype in primary CNS lymphomas.21 Data are limited on the association of COO 
subtype with the risk of secondary CNS disease in DLBCL, with only one 
retrospective study published to date. Savage and colleagues showed that ABC (or 
non-GCB) DLBCL is associated with higher CNS relapse risk.9 In a multivariate 
analysis including COO subtype, dual-expression status of BCL2 and MYC proteins, 
and CNS-IPI, only high CNS-IPI score and BCL2/MYC dual-expression were 
significantly associated with CNS relapse risk.9  
GOYA is a multicenter, randomized, phase III trial (NCT01287741) investigating the 
efficacy and safety of obinutuzumab (G) or R plus CHOP in patients with previously 
untreated DLBCL. After a median observation time of 29.0 months, there were no 
significant differences between G-CHOP and R-CHOP for progression-free survival 
(PFS) and OS;22 3-year investigator-assessed PFS rates were 70% and 67%, 
respectively. Patients with GCB DLBCL demonstrated better outcomes than those 
with ABC or unclassified DLBCL, with 3-year PFS rates of 75%, 59%, and 63%, 
respectively. Using data from GOYA, we aimed to evaluate the impact of distinct 
COO subtypes and dual-expression of BCL2 and MYC proteins on CNS relapse risk.  
 
Methods 
Patients, treatment, and clinical assessments 
The GOYA study design is described in full elsewhere.22 Patients had previously 
untreated, histologically documented, CD20-positive DLBCL and an IPI score of ≥2, 
an IPI score of 1 (if age ≤60 years, with or without bulky disease), or an IPI score of 
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0 (with bulky disease [one lesion ≥7.5 cm]). Patients with CNS involvement at 
diagnosis were excluded.  
Patients received eight 21-day cycles of G or R plus six to eight cycles of CHOP 
chemotherapy. CNS prophylaxis with intrathecal chemotherapy was recommended 
to be given according to institutional practice. No systemic CNS-directed prophylaxis 
was administered.  
Staging investigations included computed tomography (CT) scan and bone marrow 
biopsy. Baseline lumbar puncture was recommended in patients with high-risk 
disease or with one or more of the following sites of involvement: paranasal sinuses, 
testicular, parameningeal, periorbital, paravertebral, or bone marrow. CNS relapse 
was diagnosed according to institutional practice via imaging (magnetic resonance 
imaging or CT scan), and/or presence of malignant cells in cerebrospinal fluid or 
affected tissue. The protocol was approved by the ethics committees of participating 
centers. All patients provided written informed consent. 
 
COO, immunohistochemical (IHC), and fluorescence in-situ hybridization 
(FISH) analyses  
COO classification was performed by a central laboratory based on gene-expression 
profiling using the NanoString Lymphoma Subtyping Research-Use-Only assay 
(NanoString Technologies, Seattle, WA). IHC analysis using BCL2 (clone 124) and 
MYC (clone Y69) assays (Ventana Medical Systems, Tucson, AZ) was conducted on 
slides cut from diagnostic formalin-fixed, paraffin-embedded (FFPE) blocks. Cut slide 
stability was not considered for selection of tissue sections for analysis. BCL2 protein 
expression was assessed according to the percentage of tumor cells with BCL2 
expression and staining intensity; positivity was defined as moderate or strong 
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staining in ≥50% of tumor cells. MYC positivity was defined as expression in ≥40% of 
tumor cells. IHC analyses were conducted in a central laboratory (Hematogenix, 
Chicago, IL). FISH was performed in a central laboratory (HistoGeneX, Antwerp, 
Belgium) on the diagnostic FFPE tissue sections using Vysis LSI dual-color break-
apart probes for BCL2 and MYC rearrangement detection, as previously described.23  
 
Targeted next-generation sequencing (NGS) 
Genomic DNA was extracted from diagnostic FFPE tissue sections containing ≥20% 
tumor cells. Samples were submitted to a central laboratory (Foundation Medicine, 
Cambridge, MA) for NGS-based genomic profiling. Adaptor-ligated DNA underwent 
hybrid capture for all coding exons of 465 cancer-related genes (FoundationOne 
Heme platform). Captured libraries were sequenced to a median exon coverage 
depth of >500× (DNA) using Illumina sequencing, and resultant sequences were 
analyzed for base substitutions, small insertions and deletions (indels), copy number 
alterations (focal amplifications and homozygous deletions), and gene 
fusions/rearrangements, as previously described.24 Frequent germline variants from 
the 1000 Genomes Project (dbSNP142) were removed. To maximize mutation-
detection accuracy (sensitivity and specificity) in impure clinical specimens, the test 
was previously optimized and validated to detect base substitutions at a ≥ 5% mutant 
allele frequency (MAF), indels with a ≥ 10% MAF with ≥ 99% accuracy, and fusions 
occurring within baited introns/exons with > 99% sensitivity.24 Known confirmed 
somatic alterations deposited in the Catalogue Of Somatic Mutations In Cancer 
(COSMIC v62) are called at allele frequencies ≥ 1%.25 NGS-based genomic profiling 
was performed in a subset of patients (617 of 1,418) who provided an optional 
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written informed consent; data that passed the quality check criteria were evaluable 
in 499 of 617 patients. 
 
Statistical analysis 
The event-specific, cumulative incidence of CNS relapse and time to CNS relapse 
were estimated with Kaplan-Meier statistics. The impact of variables of interest 
(CNS-IPI, COO, BCL2/MYC dual-expression status, CDKN2A alteration, and the 
GOYA study randomization stratification factors—number of planned chemotherapy 
cycles, geographical region) on CNS relapse was assessed using univariate and 
multivariate Cox regression models. In these models, the endpoint of interest was 
time to CNS relapse, defined through the manual review of patients with disease 
progression or a death event at the time of the primary analysis cut-off (29 April 
2016). The significance level, used consistently, was 5%; all tests are two-sided. No 
multiplicity adjustment was performed in order to avoid loss of power due to the low 
number of events, which is a structural limitation of such rare phenomena. The R 
statistical software package version 3.4.0,26 together with RStudio version 1.0.153,27 
was used for all analyses. 
 
Results 
Overall, 1,418 DLBCL patients, randomized and treated with G-CHOP (n = 706) or 
R-CHOP (n = 712) in GOYA, were analyzed for CNS relapse occurrence. Baseline 
characteristics are shown in Table 1. According to CNS-IPI score, 279 (19.7%) 
patients were categorized as being at low risk (0 to 1), 894 (63.0%) at intermediate 
risk (2 to 3), and 245 (17.3%) at high risk (4 to 6) of developing CNS relapse. COO 
was available for 933 patients, of whom 540 (57.9%), 243 (26.0%), and 150 (16.1%) 
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were classified as GCB, ABC, and unclassified DLBCL, respectively. Both COO and 
BCL2/MYC protein expression were available in 688 patients; 295 (42.9%) were 
BCL2/MYC dual-expressers. More patients with ABC DLBCL were BCL2/MYC dual-
expressers compared with GCB or unclassified (136 [70.5%] vs 117 [30.7%] vs 42 
[36.8%], respectively; Table 2).  
 
Incidence and outcome of CNS relapse  
After a median observation of 29.0 months (interquartile range, 24.5‒37.4), 38 
(2.7%) of the 1,418 patients developed CNS relapse (17 patients treated with 
chemotherapy only, 6 with chemotherapy and radiotherapy, 4 with radiotherapy only, 
6 received no treatment; data not available in 5 patients); 37 of these had either 
radiological signs of CNS relapse and/or infiltrated CSF. In one patient, CNS relapse 
(intraocular) was diagnosed via cytological evaluation of corpus vitreum. Most CNS 
relapses were localized in the brain parenchyma (parenchymal only, n = 27 [71.1%]; 
leptomeningeal only, n = 6 [15.8%]; parenchymal and leptomeningeal, n = 3 [7.9%]; 
intraocular, n = 1 [2.6%], and data not available, n = 1 [2.6%]). Median time to CNS 
relapse was 8.5 months (range, 0.9‒43.5). The majority (34 [89.5%]) of CNS 
relapses occurred within 2 years of randomization. The 2-year CNS relapse rate for 
the whole cohort was 2.8%. Twenty-four (63%) of 38 patients with CNS relapse were 
dead at the time of the analysis; median survival after CNS relapse was 5.9 months. 
According to CNS-IPI, 10.5% of patients with CNS relapse were categorized as low-
risk, 42.1% as intermediate-risk, and 47.4% as high-risk. Two-year CNS relapse 
rates were 0.8% (95% CI, 0.0‒1.9), 1.9% (95% CI, 0.9‒2.9), and 8.9% (95% CI, 4.7‒
12.9) for the low-, intermediate-, and high-risk CNS-IPI subgroups, respectively 
(Figure 1A). 
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Treatment arm and prophylaxis with intrathecal chemotherapy and CNS 
relapse risk 
The number of CNS relapses was similar in the G-CHOP and R-CHOP arms (20 vs 
18, respectively), with no impact of treatment arm on the incidence of CNS relapse 
(hazard ratio [HR], 1.13; 95% CI, 0.60‒2.15; P = .70). Overall, 140 (9.9%) of 1,418 
patients received intrathecal methotrexate or cytarabine or a combination of both as 
CNS relapse prophylaxis. Within the low-, intermediate-, and high-risk CNS-IPI 
groups, 16 (5.7%) of 279, 94 (10.5%) of 894, and 30 (12.2%) of 245 patients 
received intrathecal CNS relapse prophylaxis, respectively (Supplemental Table S1). 
Two-year CNS relapse rates were not different between patients who did or did not 
receive CNS relapse prophylaxis (2.8% vs 2.6%). Similarly, the number of CNS 
relapses was not different in patients treated with or without prophylaxis in any of the 
CNS-IPI categories (0.0% vs 0.9%, 1.3% vs 2.0%, and 8.5% vs 9.0% for the low-, 
intermediate-, and high-risk CNS-IPI subgroups, respectively; Supplemental Table 
S1).  
 
COO and BCL2/MYC dual-expression status and CNS relapse risk 
In patients with COO available (n = 933, 30 CNS-relapse events; Supplemental 
Table S2), 2-year CNS relapse rates were 1.4% (95% CI, 0.0‒3.2), 2.2% (95% CI, 
0.9‒3.5), and 9.6% (95% CI, 4.5‒14.5) for the low-, intermediate-, and high-risk 
CNS-IPI subgroups, respectively (Figure 1B). On univariate analysis, patients with 
ABC and unclassified DLBCL had significantly higher CNS relapse risk than those 
with GCB DLBCL (HR, 5.2; 95% CI, 2.1‒12.7; P = .0003; and HR, 4.2; 95% CI, 1.5‒
11.7; P = .005; respectively). Two-year CNS relapse rates were 6.9%, 4.8%, and 
1.3% for patients with ABC, unclassified, and GCB DLBCL, respectively. There was 
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no significant association between BCL2/MYC dual-expression and the risk of CNS 
relapse on univariate analysis (HR, 1.5; 95% CI, 0.7‒3.5, P = .3196; 2-year CNS 
relapse rate: dual-expressers 4.0% vs non-dual-expressers 2.2%; n = 688). In a 
multivariate analysis on the COO-available population (n = 933), ABC (HR, 5.2; 95% 
CI, 2.1‒12.9; P = .0004) and unclassified COO subtype (HR, 4.2; 95% CI, 1.5‒11.7; 
P = .006), and high CNS-IPI (HR, 4.0; 95% CI, 1.3‒12.3; P = .02) were associated 
with greater CNS relapse risk (Table 3). In a multivariate analysis on the population 
with COO and BCL2/MYC dual-expression status available (n = 688, 22 
CNS-relapse events; Supplemental table S2), there was no impact of BCL2/MYC 
dual-expression (HR, 0.8; 95% CI, 0.3‒2.1; P = .69) on CNS relapse risk, while ABC 
and unclassified COO subtype remained significantly associated with higher CNS 
relapse risk (Table 4). In this population, high CNS-IPI score was not significantly 
associated with CNS relapse risk, although a trend for greater risk was observed 
(HR, 2.8; 95% CI, 0.8‒9.4; P = .10). 
Overall, 560 (39.5%) of 1,418 patients had FISH results available. Twenty patients 
(3.6%) harbored both BCL2 and MYC translocations, of whom only one patient 
developed CNS relapse (FISH data were not included in the statistical analysis due 
to the low number of CNS relapses within the double-hit DLBCL).  
CNS-IPI and COO were combined (1 point for high CNS-IPI, 1 point for ABC or 
unclassified COO) to create a modified risk stratification model, CNS-IPI-C. Three 
CNS-IPI-C subgroups were identified as having low (no risk factor, n = 450 [48.2%]), 
intermediate (1 risk factor, n = 408 [43.7%]), and high (2 risk factors, n = 75 [8.0%]) 
CNS relapse risk. The 2-year CNS relapse rates were 0.5% (95% CI, 0.0‒1.3), 4.4% 
(95% CI, 2.2‒6.6), and 15.2% (95% CI, 5.4‒24.0), respectively, resulting in a 22-fold 
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higher risk of CNS relapse in the high- vs low-risk groups (Figure 2; Supplemental 
Table S3).  
 
Mutational profile 
Mutational profiles were available in 499 of 1,418 patients (12 of 38 patients with 
CNS relapse; 487 of 1,380 without CNS relapse; Supplemental Table S2). A detailed 
description of all gene alterations for the patients with CNS relapse is listed in 
Supplemental Table S4. CDKN2A was the most frequently (8 of 12; 66.6%) altered 
gene in patients who developed CNS relapse, with seven cases having homozygous 
deletion of CDKN2A and one case harboring nonsynonymous CDKN2A mutation; in 
the population of patients without CNS relapse, the prevalence of CDKN2A gene 
alterations was 21.6% (105 of 487). On multivariate analysis, CDKN2A gene 
alterations were associated with higher risk of CNS relapse (HR, 7.2; 95% CI, 2.1‒
25.0; P = .002) independent of clinical factors. The impact of CDKN2A gene 
alterations on CNS relapse risk was weakened after inclusion of COO into the model 
(HR, 3.6; 95% CI, 0.93‒14.0; P = .064). Alterations of genes known to deregulate 
NFκB signaling were also observed, such as mutations of MYD88, which were found 
in 5 (42%) of 12 cases compared with 78 (16.0%) of 487 cases in the cohort with no 
CNS relapse. Three of the 5 patients with MYD88 mutation had simultaneous 
CD79B mutation. 
 
Discussion 
The current analysis of GOYA evaluated risk factors associated with CNS relapse in 
newly diagnosed DLBCL patients treated with anti-CD20-based 
immunochemotherapy (R- or G-CHOP). We found no difference in CNS relapse risk 
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between R and G, with the incidence of CNS relapse similar in both treatment arms 
and consistent with the literature.1  
With these data, we have provided an independent validation of the CNS-IPI 
prognostic model.1 Patients with high CNS-IPI scores had significantly higher risk of 
CNS relapse than those with intermediate or low CNS-IPI scores. High CNS-IPI 
score was also an independent risk factor for CNS relapse on multivariate analysis. 
The 2-year CNS relapse rate for the high-risk CNS-IPI subgroup in GOYA (8.9%) 
was consistent with previous data from Schmitz and colleagues (10.2%).1 No 
significant difference in the incidence of CNS relapse was observed between the 
intermediate- and low-risk CNS-IPI groups. This may be due to differences in 
baseline patient characteristics in the DSHNHL/MInT (testing cohort for CNS-IPI 
building) and GOYA study cohorts.1 In the current study, we confirmed that CNS-IPI 
is a valuable clinical tool for identification of DLBCL patients with high CNS relapse 
risk.  
Most primary DLBCLs of the CNS resemble the ABC subtype, suggesting that this 
biological subtype may be prone to CNS infiltration.21 In the current study, patients 
with ABC and unclassified DLBCL had significantly higher CNS relapse risk 
compared with GCB, and in the multivariate analysis, COO and a high CNS-IPI 
score were shown to be independent risk factors for CNS relapse. Previous data by 
Savage and colleagues showed that BCL2/MYC dual-expression is associated with 
higher probability of CNS relapse.9 Given the association of the ABC subtype with 
dual-expression of BCL2 and MYC proteins, we analyzed whether the higher risk of 
CNS relapse, at least in patients with ABC DLBCL, is related to the high prevalence 
of BCL2/MYC dual-expression. Surprisingly, we did not observe a higher incidence 
of CNS relapse in BCL2/MYC dual-expressers compared with non-dual-expressers 
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in univariate or multivariate analyses, which may be due to the higher prevalence of 
BCL2/MYC dual-expression (driven by a high rate of MYC positivity) in the GOYA 
study compared with the population in Savage and colleagues (42.1% vs 29.7%, 
respectively).9,23 The reason for the high rate of MYC positivity detected in the GOYA 
study is not entirely clear. One possible explanation is that the proportion of patients 
enrolled with low IPI scores (or low CNS-IPI) was relatively low, and there was 
therefore a high proportion of high-risk patients who are more likely to be BCL2/MYC 
dual expressers. Larger studies may provide further insight.  
Primary CNS lymphomas frequently, if not uniformly, exhibit biallelic loss of 
CDKN2A, resulting in cell cycle and p53 pathway deregulation, or mutations of 
MYD88 and CD79B, thereby deregulating NFκB and B-cell receptor signaling.21,28-31 
Although data on the mutational profile were only available for a limited number of 
patients, CDKN2A loss and mutation of MYD88 were the most commonly observed 
alterations in patients with CNS relapse. In the multivariate analysis, CDKN2A loss 
was associated with higher risk of CNS relapse independent of clinical factors. 
However, the impact of CDKN2A loss on the risk of CNS relapse was weaker in a 
model that included COO, probably due to the association of CDKN2A alterations 
with the ABC subtype, which has been demonstrated in GOYA as well as other 
studies.32,33 Due to the limited number of patients with CNS relapse and mutational 
profile data available in the GOYA study, further studies are needed to confirm our 
hypothesis and to explore the impact of specific gene alterations on the risk of CNS 
relapse, especially in the context of particular COO subtypes.  
Because ABC/unclassified COO subtypes and high CNS-IPI were independent risk 
factors for CNS relapse, we combined both factors to improve the risk stratification 
ability of CNS-IPI, resulting in a modified CNS-IPI-C model. CNS-IPI-C allowed the 
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identification of three subgroups with different 2-year CNS relapse risks. This 
incorporation of biomarkers into the CNS-IPI-C model improved the discrimination of 
subgroups with a very low and high 2-year CNS relapse risk compared with the 
CNS-IPI model (2-year relapse rate in low- and high-risk subgroups 0.5% vs 1.4% 
and 15.2% vs 9.6%, respectively). This could help identify patients who should 
undergo a more comprehensive examination of the CNS to exclude asymptomatic 
CNS lymphoma involvement. It may also identify patients who could potentially 
benefit from treatment with effective prophylaxis to reduce CNS relapse risk.34,35 Last 
but not least, CNS-IPI-C identifies a large subgroup of patients with a very low risk of 
CNS relapse who could be spared invasive diagnostic and prophylactic 
interventions. However, it must be noted that CNS-IPI-C needs to be validated in an 
independent cohort of DLBCL patients before its potential clinical use.  
There is growing evidence that CNS prophylaxis with intrathecal methotrexate is not 
sufficient to prevent CNS relapse.5,36 Some trials indicate that intravenous high-dose 
methotrexate (3 g/m2) can prevent CNS relapse;37 however, treatment can be 
associated with significant toxicity, and an acceptable risk-benefit ratio should be 
carefully considered. Overall, 9.9% of patients were treated with prophylactic 
intrathecal chemotherapy in GOYA. We did not observe a significant difference in the 
incidence of CNS relapse in patients who received intrathecal chemotherapy 
compared with those who did not, neither in the whole cohort nor in the different risk 
groups according to CNS-IPI. It must be noted, however, that GOYA was not 
designed to assess the impact of CNS prophylaxis on CNS relapse risk. CNS 
prophylaxis was indicated and administered upon investigator decision, based on 
institutional practice, resulting in heterogeneous schedules and doses. Randomized 
clinical trials would be required to define appropriate CNS prophylaxis in DLBCL. 
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In conclusion, using the largest prospective dataset of previously untreated DLBCL 
with relevant biomarker data to date, we validated the CNS-IPI clinical prognostic 
model and demonstrated that ABC and unclassified DLBCL are associated with 
higher CNS relapse risk compared with GCB DLBCL. Combining CNS-IPI and COO 
helped to improve stratification of DLBCL patients with different CNS relapse risks.  
18 
Acknowledgments 
The authors thank the GOYA study team, investigators, nurses, and patients for their 
contributions and participation. GOYA was sponsored by F. Hoffmann-La Roche Ltd 
with scientific support from the Fondazione Italiana Linfomi. Third-party editorial 
assistance, under the direction of MK, was provided by Lynda McEvoy of Gardiner-
Caldwell Communications, and was funded by F. Hoffmann-La Roche Ltd. 
 
Role of the funding source  
The funder was involved in trial design, administration or conduct of study 
procedures, coordination of data collection, and data analysis and interpretation. 
Corresponding authors (M.K. and M.T.) and Roche authors (E.A.P., E.S.G., C.B., 
M.Z.O., G.F.R., and T.N.) had access to all data in the study; all other authors had 
access to the final study report. MK had final responsibility for the decision to submit 
for publication.  
 
Authorship 
M.K., M.Z.O., G.R.F.R., T.N., and M.T. took part in conception and design of the 
analysis. L.H.S., I.B.B., F.C., J.J., M.M., D.S., U.V., F.Z., Q.Z., and M.T. provided 
study materials or patients. All authors contributed to analysing and interpreting the 
data, writing the article, and provided final approval of the manuscript. 
 
Conflicts of interest 
M.K. reports employment with F. Hoffmann-La Roche Ltd during the time of the 
analysis. L.H.S. reports consultancy and honoraria from Roche/Genentech, Amgen, 
Janssen, Celgene, AbbVie, and Seattle Genetics. I.B.B. reports advisory board 
19 
membership for F. Hoffmann-La Roche Ltd. F.C., J.J., and Q.Z. report no financial 
relationships. M.M. reports consultancy, speakers’ bureaus and advisory board 
membership for F. Hoffmann-La Roche Ltd, consultancy and advisory board 
membership for Janssen and Sandoz, consultancy for Celgene and Mundipharma, 
and consultancy and speakers’ bureaus for Takeda. D.S. reports advisory board 
membership and research funding as part of clinical trial for F. Hoffmann-La Roche 
Ltd. U.V. reports research funding, honoraria, and advisory board membership for F. 
Hoffmann-La Roche Ltd, honoraria and advisory board membership for Celgene and 
Janssen, and honoraria for Takeda and Gilead. F.Z. reports consulting or advisory 
roles for F. Hoffmann-La Roche Ltd, Janssen, Novartis, and Celgene, speakers’ 
bureaus for F. Hoffmann-La Roche Ltd, Celgene, Novartis, Gilead, and Takeda, and 
research funding for Celgene and Novartis. F.M., G.S., M.Z.O., G.R.F.R., and T.N. 
are employees of F. Hoffmann-La Roche Ltd; GRFR also reports stock ownership of 
F. Hoffmann-La Roche Ltd. E.A.P., E.S.G., and C.B. are employees of Genentech 
Inc. M.T. reports honoraria, consulting, or advisory roles, research funding and 
travel, accommodations and/or expenses for F. Hoffmann-La Roche Ltd. 
 
  
20 
REFERENCES 
1. Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic 
Index: a risk model for CNS relapse in patients with diffuse large B-cell 
lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):315-356. 
2. Kanemasa Y, Shimoyama T, Sasaki Y, et al. Central nervous system relapse 
in patients with diffuse large B cell lymphoma: analysis of the risk factors and 
proposal of a new prognostic model. Ann Hematol. 2016;95(10):1661-1669. 
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab 
compared with CHOP alone in elderly patients with diffuse large-B-cell 
lymphoma. N Engl J Med. 2002;346(4):235-242. 
4. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP 
plus rituximab therapy dramatically improved outcome of diffuse large B-cell 
lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033. 
5. Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with 
aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or 
without rituximab: an analysis of patients treated in the RICOVER-60 trial of 
the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). 
Blood. 2009;113(17):3896-3902. 
6. Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central 
nervous system relapse in patients with diffuse large B-cell lymphoma: the 
impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 
2010;21(5):1046-1052. 
7. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central 
nervous system occurrence in elderly patients with diffuse large-B-cell 
lymphoma: influence of rituximab. Ann Oncol. 2004;15(1):129-133. 
21 
8. Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement 
following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol. 
2002;13(7):1099-1107. 
9. Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and 
BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 
2016;127(18):2182-2188. 
10. El-Galaly TC, Villa D, Michaelsen TY, et al. The number of extranodal sites 
assessed by PET/CT scan is a powerful predictor of CNS relapse for patients 
with diffuse large B-cell lymphoma: an international multicenter study of 1532 
patients treated with chemoimmunotherapy. Eur J Cancer. 2017;75:195-203. 
11. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell 
lymphoma identified by gene expression profiling. Nature. 
2000;403(6769):503-11. 
12. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell 
lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 
2008;105(36):13520-13525. 
13. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of 
diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837. 
14. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-
modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298-303. 
15. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to 
predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl 
J Med. 2002;346(25):1937-1947. 
16. Jardin F, Jais JP, Molina TJ, et al: Diffuse large B-cell lymphomas with 
CDKN2A deletion have a distinct gene expression signature and a poor 
22 
prognosis under R-CHOP treatment: a GELA study. Blood. 2010;116(7):1092-
1104. 
17. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in 
diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92. 
18. Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB 
activity is required for survival of activated B cell-like diffuse large B cell 
lymphoma cells. J Exp Med. 194(12):1861-1874. 
19. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell 
lymphomas. N Engl J Med. 2008;359(22):2313-2323. 
20. Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes 
of diffuse large B-cell lymphoma using gene expression in formalin-fixed 
paraffin-embedded tissue. Blood. 2014;123(8):1214-1217. 
21. Braggio E, Van Wier S, Ojha J, et al. Genome-wide analysis uncovers novel 
recurrent alterations in primary central nervous system lymphomas. Clin 
Cancer Res. 2015;21(17):3986-3994. 
22. Vitolo U, Trneny M, Belada D, et al. Obinutuzumab or rituximab plus 
cyclophosphamide, doxorubicin, vincristine, and prednisone in previously 
untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529-
3537. 
23. Sehn LH, Oestergaard MZ, Trněný M, et al. Prognostic impact of Bcl2 and 
Myc expression and translocation in untreated DLBCL: results from the phase 
III GOYA study. Hematol Oncol. 2017;35(S2):131-133. 
24. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a 
clinical cancer genomic profiling test based on massively parallel DNA 
sequencing. Nat Biotechnol. 2013;31(11):1023-1031. 
23 
25. Forbes SA, Bindal N, Bamford S, et al: COSMIC: Mining complete cancer 
genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 
39 (database issue). 2011: D945–50. 
26. R Core Team (2017). R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria. URL 
https://www.R-project.org/. Accessed June 2018. 
27. RStudio Team (2016). RStudio: Integrated Development for R. RStudio, Inc., 
Boston, MA. URL: http://www.rstudio.com/. Accessed June 2018. 
28. Chapuy B, Roemer MG, Stewart C, et al. Targetable genetic features of 
primary testicular and primary central nervous system lymphomas. Blood. 
2016;127(7):869-881. 
29. Cobbers JM, Wolter M, Reifenberger J, et al. Frequent inactivation of 
CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol. 1998;8(2):263-
276. 
30. Bruno A, Boisselier B, Labreche K, et al. Mutational analysis of primary 
central nervous system lymphoma. Oncotarget. 2014;5(13):5065-5075. 
31. Yamada S, Ishida Y, Matsuno A, et al. Primary diffuse large B-cell lymphomas 
of central nervous system exhibit remarkably high prevalence of oncogenic 
MYD88 and CD79B mutations. Leuk Lymphoma. 2015;56(7):2141-45. 
32. Bolen C, Klanova M, Trneny M, et al. Systematic analysis of the prognostic 
impact of somatic mutations in diffuse large B-cell lymphoma (DLBCL) with 
evaluation of cell-of-origin dependence: results from the phase 3 GOYA trial in 
previously untreated DLBCL. Blood. 2017;130(S1):2729. 
33. Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse 
large B-cell lymphoma. Cell. 2017;171(2):481-494.   
24 
34. Wilson WH, Bromberg JE, Stetler-Stevenson M, et al. Detection and outcome 
of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt 
lymphoma. Haematologica. 2014;99(7):1228-1235. 
35. Muniz C, Martin-Martin L, Lopez A, et al. Contribution of cerebrospinal fluid 
sCD19 levels to the detection of CNS lymphoma and its impact on disease 
outcome. Blood. 2014;123(12):1864-1869. 
36. Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in 
diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann 
Hematol. 2011;90(7):809-818. 
37. Ferreri AJ, Bruno-Ventre M, Donadoni G, et al. Risk-tailored CNS prophylaxis 
in a mono-institutional series of 200 patients with diffuse large B-cell 
lymphoma treated in the rituximab era. Br J Haematol. 2015;168(5):654-662. 
 
  
25 
TABLES 
 
Table 1. Key baseline clinical characteristics (CNS-IPI risk factors, CNS-IPI score) of 
patients who developed CNS relapse compared with patients with no CNS relapse 
and the overall GOYA study population 
 
Characteristic 
CNS relapse No CNS relapse All patients 
(n = 38) (n = 1,380) (N = 1,418) 
Median age (range), years  66.5 (21-81) 61.0 (18-86) 62.0 (18-86) 
<60 13 (34.2) 591 (42.8) 604 (42.6) 
≥60 25 (65.8) 789 (57.2) 814 (57.4) 
ECOG PS 
0-1 31 (81.6) 1,200 (87.0) 1,231 (86.9) 
2-3 7 (18.4) 179 (13.0) 186 (13.1) 
Ann Arbor Stage 
I and II 4 (10.5) 337 (24.4) 341 (24.1) 
III and IV 34 (89.5) 1,042 (75.6) 1,076 (75.9) 
Elevated LDH 26 (68.4) 790 (57.5) 816 (57.7) 
Number of extranodal sites 
0-1 15 (39.5) 900 (65.2) 915 (64.5) 
>1 23 (60.5) 480 (34.8) 503 (35.5) 
Involvement of kidneys  
and/or adrenal glands 11 (28.9) 80 (5.8) 91 (6.4) 
CNS-IPI  
Low (0-1) 4 (10.5) 275 (20.0) 279 (19.7) 
Intermediate (2-3) 16 (42.1) 878 (63.6) 894 (63.0) 
High (4-6) 18 (47.4) 227 (16.5) 245 (17.3) 
NOTE. Data are presented as No. (%) unless otherwise noted. Data for ECOG PS and Ann 
Arbor Stage were not available in one case, and data on LDH were not available in five 
cases. Differences ≥ 10% between CNS relapse/no relapse groups are highlighted in bold.  
CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group 
performance status; IPI, International Prognostic Index; LDH, lactate dehydrogenase.  
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Table 2. Key clinical and biomarker characteristics of patients with distinct COO 
subtypes: GCB, Unclassified, and ABC DLBCL 
 
Characteristic 
GCB 
(n = 540) 
Unclassified 
(n = 150) 
ABC 
(n = 243) 
Median age (range), years 62.5 (18-83) 62.0 (21-83) 64.0 (29-86) 
<60 228 (42.2) 59 (39.3) 70 (28.8) 
≥60 312 (57.8) 91 (60.7) 173 (71.2) 
ECOG PS 
0-1 475 (88.1) 126 (84.0) 209 (86.0) 
2-3 64 (11.9) 24 (16.0) 34 (14.0) 
Ann Arbor Stage 
I and II 146 (27.0) 34 (22.7) 52 (21.4) 
III and IV 394 (73.0) 116 (77.3) 191 (78.6) 
Elevated LDH 308 (57.1) 76 (50.7) 169 (70.4) 
Number of extranodal sites    
0-1 355 (65.7) 95 (63.3) 158 (65.0) 
>1 185 (34.3) 55 (36.7) 85 (35.0) 
Involvement of kidneys  
and/or adrenal glands 36 (6.7) 9 (6.0) 13 (5.3) 
CNS-IPI  
Low (0-1) 115 (21.3) 29 (19.3) 28 (11.5) 
Intermediate (2-3) 335 (62.0) 97 (64.7) 164 (67.5) 
High (4-6) 90 (16.7) 24 (16.0) 51 (21.0) 
BCL2/MYC dual-expression n = 381 n = 114 n = 193 
Non-dual expressers 264 (69.3) 72 (63.2) 57 (29.5) 
Dual expressers 117 (30.7) 42 (36.8) 136 (70.5) 
NOTE. Data are presented as No. (%) unless otherwise noted. Data for ECOG PS were not 
available in one case, and data on LDH were not available in three cases.  
ABC, activated B-cell–like; CNS, central nervous system; COO, cell-of-origin; DLBCL, 
diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group 
performance status; GCB, germinal center B-cell–like; IPI, International Prognostic Index; 
LDH, lactate dehydrogenase.  
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Table 3. Results of multivariate Cox regression analysis on factors associated with 
CNS relapse in the COO-available population (n = 933), CNS relapses (n = 30) 
 
Factor HR* 95% CI P value 
CNS-IPI intermediate (v low) 0.88 0.29-2.74 .8312 
CNS-IPI high (v low) 3.97 1.28‒12.33 .0172 
ABC COO (v GCB) 5.18 2.09‒12.87 .0004 
Unclassified COO (v GCB) 4.18 1.50‒11.66 .0062 
*Adjusted for study randomization stratification factors (number of planned chemotherapy 
cycles, geographic region).  
ABC, activated B-cell–like; CNS, central nervous system; COO, cell-of-origin; GCB, germinal 
center B-cell–like; HR, hazard ratio; IPI, International Prognostic Index. 
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Table 4. Results of multivariate Cox regression analysis on factors associated with 
CNS relapse in the COO and BCL2/MYC dual-expression status-available 
population (n = 688), CNS relapses (n = 22) 
 
*Adjusted for study randomization stratification factors (number of planned chemotherapy 
cycles, geographic region).  
ABC, activated B-cell–like; CNS, central nervous system; COO, cell-of-origin; GCB, germinal 
center B-cell–like; HR, hazard ratio; IPI, International Prognostic Index. 
 
 
  
Factor HR* 95% CI P value 
CNS-IPI intermediate (v low) 0.75 0.23‒2.45 .6378 
CNS-IPI high (v low) 2.76 0.81‒9.42 .1042 
ABC COO (v GCB) 4.78 1.49‒15.29 .0084 
Unclassified COO (v GCB) 4.24 1.32‒13.61 .0151 
BCL2/MYC dual expresser  
(v non-dual expresser) 0.83 0.34‒2.06 .6931 
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FIGURE LEGENDS 
 
Figure 1. Risk of CNS relapse by CNS-IPI categories in (A) overall GOYA study 
population (N = 1,418), and (B) COO available population (n = 933). CNS, central 
nervous system; COO, cell-of-origin; EoT, end of treatment; IPI, International 
Prognostic Index.  
 
Figure 2. Risk of CNS relapse by CNS-IPI and COO (CNS-IPI-C) in the COO 
available population (n = 933). ABC, activated B-cell–like; CNS, central nervous 
system; COO, cell-of-origin; EoT, end of treatment; H-R, high risk; IPI, International 
Prognostic Index; I-R, intermediate risk; L-R, low risk; UNCL, unclassified. 
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